In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ventana Medical Systems Inc.

Division of Roche
www.ventana.com

Latest From Ventana Medical Systems Inc.

Lilly Moves Closer To NDA Filing For RET Inhibitor In NSCLC

Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.

Business Strategies Clinical Trials

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.

Deals Cancer

US Approvals Analysis: 510(k) Clearances Spiked In May

In May, US FDA achieved its highest monthly total of 510(k)s clearances in more than two years. Here's a snapshot of the agency's approval and clearance activity last month from Medtech Insight's Approvals Tracker.

Approvals Medical Device

Roche Pushes The Boundaries Of Cancer Immunotherapy

Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.

Research and Development Strategies Market Intelligence
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register